特利加压素
肝肾综合征
血管活性肠肽
奥曲肽
医学
门脉高压
肝硬化
血管活性
生长抑素
内科学
加压素
胃肠病学
重症监护医学
神经肽
受体
出处
期刊:Current Opinion in Endocrinology, Diabetes and Obesity
[Ovid Technologies (Wolters Kluwer)]
日期:2020-02-01
卷期号:27 (1): 22-27
被引量:1
标识
DOI:10.1097/med.0000000000000528
摘要
Purpose of review To summarize the use of gastrointestinal peptides in the management of portal hypertension. Recent findings Vasoactive peptides are commonly used in the management of acute variceal hemorrhage and hepatorenal syndrome, which are portal hypertensive complications of cirrhosis. The main vasoactive peptides that are used are somatostatin and its long-acting analogue octreotide, and vasopressin and its analogue terlipressin. Early initiation of vasoactive peptides in the management of acute variceal hemorrhage and hepatorenal syndrome is associated with improved outcomes. Octreotide is the available vasoactive peptide in the Unites States. Recent developments and ongoing clinical trials may improve our understanding of hepatorenal syndrome and influence the use of vasoactive peptides, particularly terlipressin. Summary Here, we review the literature on the use of vasoactive peptides in the management of acute variceal hemorrhage and hepatorenal syndrome.
科研通智能强力驱动
Strongly Powered by AbleSci AI